Intranasal steroids in treatment of allergic rhinitis

Allergic rhinitis (AR) is one of the most common diseases affecting adults and children. AR is often a part of a systemic inflammatory process associated with other inflammatory conditions, including allergic conjunctivitis (Ac), rhinosinusitis and asthma. Undertreated AR impairs quality of life, exacerbates asthma and is a major factor in asthma development. There is a strong recommendation that clinicians recommend intranasal steroids (INS) for patients with a clinical diagnosis of AR whose symptoms affect their quality of life. All modern INS are minimally bioavailable and similar with regard to efficacy and safety at the recommended starting dose. however, differences in patient preference and safety of use during pregnancy may contribute to primary care physicians’ selection of an INS therapy for their patients.